SubsidieMeestersImmune Photo-Activated Cancer Therapy for the Treatment of Upper Tract Urothelial Cancer (UTUC) and other solid tumours
Padeliporfin-VTP therapy offers a minimally invasive treatment for UTUC by using laser-activated photosensitizers to eliminate tumors while preserving organ function, aiming for regulatory approval and market entry.
Projectdetails
Introduction
UTUC is a non-systemically treatable cancer that forms in the renal pelvis or ureter, frequently recurring due to ineffective systemic chemotherapy. With 5-10% of urothelial cancers being UTUC, current surgical treatment solutions pose significant hardships on patients and decrease their quality of life.
Proposed Solution
Our proprietary solution, Padeliporfin-VTP therapy, offers a minimally invasive and effective alternative to surgery. This therapy delivers an inactive photosensitizer drug that is precisely activated in the tumour micro-environment by non-thermal laser light.
Mechanism of Action
- Immediately impedes the tumour's blood supply
- Leads to cell death with minimal effect on healthy tissues
Benefits of Treatment
This treatment not only effectively eliminates tumours but also preserves organ functionality for potential future treatments.
Project Leadership
This project is led by a team of accomplished professionals in the pharmaceutical and biopharma industry, which solidifies our capability in innovating best-in-class therapeutic solutions.
Funding and Market Goals
Utilising this funding, we aim to achieve:
- Regulatory approval (TRL9)
- Scale production
- Achieve market penetration in a market projected to reach €4.39B by 2032.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.498.730 |
| Totale projectbegroting | € 2.498.730 |
Tijdlijn
| Startdatum | 1-12-2024 |
| Einddatum | 30-11-2026 |
| Subsidiejaar | 2024 |
Partners & Locaties
Projectpartners
- IMPACT BIOTECH LTDpenvoerder
Land(en)
Vergelijkbare projecten binnen EIC Accelerator
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implementNEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials. | EIC Accelerator | € 2.500.000 | 2023 | Details |
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer careNectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology. | EIC Accelerator | € 2.499.998 | 2024 | Details |
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness. | EIC Accelerator | € 2.499.999 | 2024 | Details |
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineeringThe project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer. | EIC Accelerator | € 2.434.790 | 2025 | Details |
Innovative approach to an Individualised T-Cell Immunotherapy for cancer, using Personalised Tumour Trained Lymphocytes (pTTL) that is reliable, cost-effective, scalable and easy to implement
NEOGAP's project aims to develop a personalized T cell therapy for solid tumors using machine learning and neoantigen stimulation, with a focus on safety and biomarker exploration in colorectal cancer trials.
First-in-class anti-PVR mAb NTX1088 - a novel oncology drug that unlocks the power of human immune system and revolutionizes cancer care
Nectin Therapeutics is developing NTX1088, a monoclonal antibody that activates the immune system against cancer, currently in Phase I trials to improve patient outcomes in oncology.
A Novel ‘Radiotherapy from Within’ Platform Technology for the Targeted Treatment of Solid Tumours Called ‘BAT-90’
BetaGlue's BAT-90 is a personalized radiotherapy platform that targets solid tumors like HCC and PDAC, minimizing off-target effects through percutaneous administration, showing promising safety and effectiveness.
Novel peptide-based therapeutics for reprogramming the tumour stroma extracellular matrix using molecular modelling and computational engineering
The project aims to develop TAX2, a novel peptide therapy targeting the tumor microenvironment to inhibit solid tumor progression and enhance immunotherapy efficacy, with a focus on ovarian cancer.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Innovative Photoactivated Ruthenium Chemotherapy to treat eye cancerPACT4EYE aims to develop a novel photoactivated chemotherapy using a ruthenium prodrug to treat uveal melanoma, enhancing patient outcomes by targeting tumors in hypoxic conditions. | EIC Transition | € 2.499.998 | 2023 | Details |
Chemogels voor de behandeling van uitgezaaide buikvlieskankerUPyTher ontwikkelt innovatieve hydrogels voor lokale chemotherapie bij buikvlieskanker om de effectiviteit van behandelingen te verbeteren. | Mkb-innovati... | € 20.000 | 2023 | Details |
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELiminationSCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy. | EIC Pathfinder | € 4.554.301 | 2025 | Details |
SupraTagEen innovatieve hydrogel voor gecontroleerde medicijnafgifte bij peritoneale carcinomatose verbetert de behandeling en vermindert bijwerkingen. | Mkb-innovati... | € 200.200 | 2020 | Details |
PRO CellecTPan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren. | Mkb-innovati... | € 20.000 | 2021 | Details |
Innovative Photoactivated Ruthenium Chemotherapy to treat eye cancer
PACT4EYE aims to develop a novel photoactivated chemotherapy using a ruthenium prodrug to treat uveal melanoma, enhancing patient outcomes by targeting tumors in hypoxic conditions.
Chemogels voor de behandeling van uitgezaaide buikvlieskanker
UPyTher ontwikkelt innovatieve hydrogels voor lokale chemotherapie bij buikvlieskanker om de effectiviteit van behandelingen te verbeteren.
Specific Conjugation of Antibodies to Lipid Photo-peroxidised cancer tissues for their immunogenic ELimination
SCALPEL aims to revolutionize cancer treatment by using photodynamic therapy to destroy tumors while marking surviving cells for immune system targeting, potentially offering a curative photoimmunotherapy.
SupraTag
Een innovatieve hydrogel voor gecontroleerde medicijnafgifte bij peritoneale carcinomatose verbetert de behandeling en vermindert bijwerkingen.
PRO CellecT
Pan Cancer T ontwikkelt een innovatieve TCR-gebaseerde therapie voor hard-to-treat kankers, met een strategisch plan om de commerciële haalbaarheid en waarde te maximaliseren.